Staff Reports
Health and Human Services Secretary Robert F. Kennedy Jr. is reportedly moving to install Steven C. Quay as the next head of the National Institute of Allergy and Infectious Diseases. The news, first reported by a major outlet, says Quay is in “final vetting.” That matters because Quay is best known not as a career infectious‑disease director but as the Atossa Therapeutics CEO who loudly pushed the lab‑leak theory about COVID‑19. For readers who want less theater and more answers, the central question is simple: has HHS picked a reformer or launched a political power play?
The POLITICO scoop and where things stand
The story being reported this week is not an old wrinkle dusted off. POLITICO says Secretary Kennedy selected Quay and that Quay is undergoing final vetting by HHS. There is a catch: neither HHS nor NIH has put out an official announcement, and NIH still lists Acting Director John Powers III on its directory. In other words, we have an anonymous source and a lot of speculation dressed up as inevitability. That’s not unusual in politics, but it’s why readers should demand transparency before agencies are reshaped on rumor.
Who is Steven Quay?
Atossa CEO, lab‑leak advocate, policy agitator
Quay runs Atossa Therapeutics and has spent years arguing that SARS‑CoV‑2 likely escaped from a lab. He testified to Congress, wrote a book, and has repeatedly said the virus’s genome points to human engineering. Those claims put him at odds with many infectious‑disease experts, but they also made him a hero to critics of the old NIH‑Fauci era. What he is not, by background, is a traditional NIAID career scientist with decades inside federal research bureaucracy — and that difference will matter if he’s confirmed.
Why this appointment would change NIAID
NIAID runs a massive research budget and sets the tone for how the government funds and polices dangerous research. Pick a director who wants tighter oversight, and grant priorities and biosafety rules change. Pick a director who sees mainstream infectious‑disease orthodoxy as compromised, and the agency’s public messaging will shift too. Expect fights over gain‑of‑function rules, forensic standards for pathogen research, and how grants are awarded. Put bluntly: a Quay director would be a different NIAID — and that’s why the confirmation fight will be loud.
Questions to demand and what to watch next
Before anyone congratulates or condemns, three simple things should happen. HHS and NIH must confirm or deny the report on the record. Quay should explain how he will avoid conflicts of interest as Atossa’s CEO and outline any recusal plans. And Congress — especially the Senate committees that vet nominees — should press him on his scientific claims and management plan for a billion‑dollar institute. If Secretary Kennedy wants reform and real accountability, pick a leader and let the light of public review do its job. If this is politics by stealth, voters and taxpayers deserve better than whispered personnel leaks and anonymous sources.
